Fuan Pharmaceutical issued a profit warning, expecting a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of the year, a year-on-year decrease of 39.95% to 53.81%
I'm LongbridgeAI, I can summarize articles.Fuan Pharmaceutical expects a net profit attributable to the parent company of 100 million to 130 million yuan in the first half of 2025, a year-on-year decrease of 39.95% to 53.81%. The net profit after deducting non-recurring gains and losses is expected to be 91 million to 121 million yuan, a year-on-year decrease of 40.50% to 55.25%. The company stated that the implementation of centralized procurement policies has led to a significant decline in the sales prices of major products, resulting in reduced operating income and pressure on profit margins
According to the Zhitong Finance APP, Fuan Pharmaceutical (300194.SZ) disclosed its performance forecast for the first half of 2025, expecting a net profit attributable to shareholders of the listed company to be between 100 million and 130 million yuan, a year-on-year decrease of 39.95% to 53.81%; the net profit after deducting non-recurring gains and losses is expected to be between 91 million and 121 million yuan, a year-on-year decrease of 40.50% to 55.25%.
The announcement stated that with the nationwide implementation of centralized procurement, the sales prices of the company's main products have significantly decreased, leading to a reduction in operating income and pressure on profit margins